Immuron(NASDAQ) IMRN

Current Price$1.14

Market Cap$8.96M

Since IPO (2017)-89%

5 Year-77%

1 Year-36%

1 Month+3%

Immuron last closing stock price
Metric	Price	Date
Last close	USD 1.11	2026-07-24

Immuron stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.26%	USD 1.21	2026-07-17
1 month	+2.78%	USD 1.08	2026-06-24
3 month	+24.23%	USD 0.89	2026-04-24
Year to date	+45.57%	USD 0.76	2025-12-31
1 year	-36.21%	USD 1.74	2025-07-24
3 year	-45.05%	USD 2.02	2023-07-25
5 year	-77.11%	USD 4.85	2021-05-27
Since inception	-89.41%	USD 10.48	2017-03-02

Immuron Financials at a Glance

Market Cap

$8.96M

Revenue (TTM)

A$13.04M

Net Income (TTM)

-A$8.50M

EPS (TTM)

-$0.48

P/E Ratio

-2.31

Dividend

$0.00

Beta (Volatility)

0.68 (Low)

Dividend

$0.00

Beta (Volatility)

0.68 (Low)

Price

$1.14

Volume

19,201

Open

$1.17

Price

$1.14

Volume

19,201

Open

$1.17

Previous Close

$1.11

Daily Range

$1.08 - $1.17

52-Week Range

$0.68 - $2.39

Estimated Earnings Date

Aug 28, 2026

Dividend

$0.00

Beta (Volatility)

0.68 (Low)

Price

$1.14

Volume

19,201

Open

$1.17

Previous Close

$1.11

Daily Range

$1.08 - $1.17

52-Week Range

$0.68 - $2.39

Estimated Earnings Date

Aug 28, 2026

IMRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuron

Immuron Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of polyclonal antibodies. With operations in Australia, the United States, and other international markets, the company focuses on innovative healthcare solutions.

Products and Services

Travelan: An OTC medicine that reduces the risk of traveler's diarrhea
Protectyn: An immune supplement supporting digestive function and liver health
IMM-124E: A pipeline candidate in Phase III trials for anti-viral activity

Growth Outlook

Recent revenue growth of 24.7% in the latest quarter compared to the previous
Strong pipeline with two candidates in advanced clinical trials
Strategic collaborations with military research institutions enhance development potential

Financial Highlights

Quarterly revenue of 4.1 million AUD, a significant increase from previous quarters
Current ratio of 8.04 indicates strong liquidity position
Cash reserves of approximately 9.99 million AUD support ongoing operations

Immuron Limited is positioned in the biotechnology sector, focusing on innovative treatments that address significant health challenges. The company's flagship products, Travelan and Protectyn, cater to growing consumer demand for health supplements and preventive care. The ongoing clinical trials for IMM-124E and IMM-529 highlight the company's commitment to expanding its product offerings and addressing unmet medical needs. Recent financial performance indicates a positive trajectory, with notable revenue growth and a robust liquidity position, suggesting that Immuron is well-equipped to navigate the evolving healthcare landscape.

AI Generated • Jul 20, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Steven Lydeamore, MBA

Website

www.immuron.com

Headquarters

Carlton, VIC 3130, AU

IMRN Financials

Key Financial Metrics (TTM)

Gross Margin

63.69%

Operating Margin

-68.38%

Net Income Margin

-62.14%

Return on Equity

-43.95%

Return on Capital

-65.59%

Return on Assets

-30.69%

Earnings Yield

-43.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.96M

Shares Outstanding

8.07M

Volume

19.20K

Avg. Volume

247.82K

Financials (TTM)

Gross Profit

A$8.42M

Operating Income

-A$9.05M

EBITDA

-A$9.08M

Operating Cash Flow

-A$9.64M

Capital Expenditure

-A$4.67K

Free Cash Flow

-A$9.64M

Cash & ST Invst.

A$9.99M

Total Debt

A$0.00

Immuron Performance Analysis

Immuron annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-06-30	AUD 554,984	N/A
2023	2023-06-30	AUD 1,214,033	118.8%
2024	2024-06-30	AUD 3,213,215	164.7%
2025	2025-06-30	AUD 4,719,288	46.9%

Immuron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-30	100.0%
Q3	2025-03-31	-58.8%
Q4	2025-06-30	100.0%
Q2	2025-12-31	N/A

Immuron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-06-30	AUD -0.36	N/A
2023	2023-06-30	AUD -0.45	22.9%
2024	2024-06-30	AUD -0.80	78.4%
2025	2025-06-30	AUD -0.59	-26.7%

Immuron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-30	-100.0%
Q3	2025-03-31	46.3%
Q4	2025-06-30	-103.4%
Q2	2025-12-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

A$4.11M

+105.7%

Gross Profit

A$2.60M

+96.1%

Gross Margin

63.42%

N/A

Market Cap

$8.96M

N/A

Market Cap/Employee

$1.28M

N/A

Employees

N/A

Net Income

-A$1.88M

-51.4%

EBITDA

-A$2.30M

-81.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

A$9.99M

+29.1%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$2.52M

+119.6%

Inventory

A$2.24M

+47.6%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-30.69%

N/A

Return on Invested Capital

-38.50%

N/A

Free Cash Flow

-A$2.43M

-21.9%

Operating Cash Flow

-A$2.43M

-21.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$0.90-2.17%

CLRBCellectar Biosciences, Inc.

CLRBCellectar Biosciences, Inc.$2.41-2.43%

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$3.83+0.52%

APMAptorum Group Limited

APMAptorum Group Limited$8.99-5.77%

EVGNEvogene Ltd.

EVGNEvogene Ltd.$0.54-0.04%

TRAWTraws Pharma, Inc.

TRAWTraws Pharma, Inc.$0.49-6.13%

IMNNImunon, Inc.

IMNNImunon, Inc.$1.51-9.04%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

NUNu Holdings

NUNu Holdings$14.09-0.01%

TAT&T

TAT&T$24.13+0.05%

Questions About IMRN

What is the current price of Immuron?

Immuron is trading at $1.11 per share.

What is the 52-week range for Immuron?

Over the past 52 weeks, Immuron has traded between $0.68 and $2.39.

How much debt does Immuron have?

As of the most recent reporting period, Immuron reported total debt of A$0.00.

How much cash does Immuron have on hand?

Immuron reported A$1.85M in cash and cash equivalents in its most recent financial results.

What is Immuron’s dividend yield?

Immuron does not currently have a dividend yield.

Immuron(NASDAQ) IMRN

Immuron Financials at a Glance

IMRN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immuron

IMRN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immuron Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMRN

What is the current price of Immuron?

What is the 52-week range for Immuron?

How much debt does Immuron have?

How much cash does Immuron have on hand?

What is Immuron’s dividend yield?

Premium Investing Services